McKesson Becomes Authorized US Distributor for LYMPHIR Cancer Treatment.

Citius Oncology has entered into a distribution agreement with McKesson Corporation, one of North America's largest pharmaceutical distributors, to distribute LYMPHIR, a novel immunotherapy approved by the FDA for treating relapsed or refractory cutaneous T-cell lymphoma, according to MarketScreener. This agreement completes Citius Oncology's core US distribution network for LYMPHIR.

Citius Oncology, Inc. has finalized its U.S. distribution strategy by signing an agreement with McKesson Corporation, one of the largest pharmaceutical distributors in North America. This strategic partnership will see McKesson serve as an authorized distributor for LYMPHIR, a novel immunotherapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

The agreement with McKesson completes Citius Oncology's core U.S. distribution network for LYMPHIR, which now includes all three of the largest pharmaceutical distributors in the country. This milestone ensures broad and reliable access to the therapy in preparation for its planned commercial launch in the fourth quarter of 2025.

"With a complete top-tier distribution network in place, we believe we are well-positioned to deliver on our promise to the CTCL community and execute a successful launch," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals.

McKesson Corporation, headquartered in Irving, Texas, is a global leader in healthcare supply chain management, medical products distribution, and pharmaceutical logistics. The company supports thousands of hospitals, clinics, and pharmacies across the United States, making it a critical partner for enabling access to life-saving therapies like LYMPHIR.

This strategic move by Citius Oncology complements its ongoing commercialization activities, including inventory readiness, market access infrastructure, permanent J-code assignment (J9161), NCCN guideline inclusion, and a robust suite of provider and patient education resources.

About LYMPHIR™ (denileukin diftitox-cxdl)

LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors.